3 doses of mRNA COVID vaccine show advantage against severe outcomes The authors said COVID-19 infection can result in a "brainstem insult" that results in clusters of physical long-COVID symptoms. CIDRAP

A team led by US Food and Drug Administration (FDA) researchers studying Medicare claims data during the early Omicron SARS-CoV-2 variant months conclude that a third dose of mRNA COVID-19 vaccine provides significant protection against hospitalization and death compared with two doses but wanes substantially after 4 months.

...